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Abstract
Introduction: Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable
hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve
downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy
after LEN treatment in unresectable HCC remains largely unknown.
Patient concerns: Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC;
case 2, a 72-year-old womanwith nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old manwith a history of alcoholic
cirrhosis-based HCC.
Diagnosis: In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed
as Barcelona Clinic Liver Cancer (BCLC) stage B.
Interventions: In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining
liver function.
Outcomes: In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected,
indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After
successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation
period (median 10 months).
Lessons: This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or
ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while
maintaining the hepatic functional reserve.
Abbreviations: AFP = a-fetoprotein, ALBI = albumin-bilirubin, BCLC = Barcelona Clinic Liver Cancer, CT = computed
tomography, cTAE = conventional-transcatheter arterial embolization, HCC = hepatocellular carcinoma, LEN = lenvatinib, mALBI =
modified ALBI, mRECIST = modified response evaluation criteria in solid tumors, MTAs = molecular targeting agents, PR = partial
response, RECIST = response evaluation criteria in solid tumors, SOR = sorafenib.
Keywords: ablation, conversion therapy, hepatic functional reserve, hepatocellular carcinoma, lenvatinib, resection
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Hepatocellular carcinoma (HCC) is the fifth most commonly
diagnosed malignancy and the second leading cause of cancer-
related deaths worldwide.[1] A recent phase III trial, REFLECT,
indicated that lenvatinib (LEN) was non-inferior to sorafenib
(SOR) as a first-line treatment for unresectable HCC.[2] Based on
these results, LEN was approved in Japan and other countries, as
the first-line systemic treatment for patients with unresectable
advanced HCC. LEN has shown a remarkably high response rate
in HCC patients compared to other known molecular targeting
agents (MTAs).[2]
It has been recently reported that conversion from unresectable
to resectable metastatic gastrointestinal cancer through advances
in systemic chemotherapy, termed as “conversion therapy”,
could improve the prognosis of patients.[3,4] Similarly, in patients
with unresectable HCC, if an incurable disease apparently
disappears or is well-controlled during primary treatment,
surgery to excise any macroscopically remaining disease, with
curative intent, could be possible. However, the feasibility and
efficacy of conversion therapy in HCC remain unknown.
In this report, 3 cases of patients with unresectable HCC
who successfully achieved conversion therapy are described.
These patients were treated with LEN, and eventually had
resection or ablation after showing good clinical and radiological
response.
2. Case reports
Table 1 provides the summary of clinical characteristics and
courses of 3 patients with unresectable HCC who underwent
conversion therapy after LEN treatment. Written informed
consent was obtained from the 3 patients for publication of this
case report.
2.1. Case 1
A 69-year-old man, with a history of alcoholic cirrhosis,
presented with abdominal pain. The cirrhosis was classified as
Child-Pugh 5 and modified ALBI (mALBI) grade 2A. Computed
tomography (CT) showed a large hypervascular liver tumor,
measuring 7.3cm. Many satellite nodules had disseminated in all
the liver segments (Fig. 1a). Based on the presence of typical
arterial uptake, with portal wash-out on dynamic CT and
elevated a-fetoprotein (AFP) level (1637ng/ml; normal <10ng/
ml), HCC in BCLC stage B was diagnosed.
Further, since the tumor had extrahepatic growth accompa-
nied by abdominal pain and progression of anemia and ascites
was seen, this case was diagnosed as ruptured HCC. Therefore,
an emergency conventional-transcatheter arterial embolization
(cTAE) and angiography, targeting the main tumor, were
performed (Fig. 1b).
However, a follow-up CT evaluation after 1 month revealed
that lipiodol was washed out from more than half of the tumor,
and the tumor marker level increased from 866 to 1637mg/dl. In
addition, there were concerns about the possible locoregional
recurrence and peritoneal seeding. Thus, LEN was orally
administrated at 12mg/day. No severe side effects were observed,
except grade 2 hypertension and palmar-plantar erythrodyses-
thesia at days 24 and 36, respectively. Two months after the
initiation of LEN therapy, the patient had partial response (PR),
according to the response evaluation criteria in solid tumors
(RECIST) and the modified RECIST (mRECIST) criteria.
Additionally, the AFP level markedly decreased from 1637 to
4ng/ml and was sustained within the normal range with
continued therapy. After 6 months of LEN treatment, a
follow-up CT examination showed that the tumor burden had
significantly decreased, along with the presence of extensive
necrotic areas; thus suggesting antitumor activity of LEN,
especially as an angiogenesis inhibitor (Fig. 1c). We further
confirmed by CT andmagnetic resonance imaging that there were
no satellite nodules in the liver tissue surrounding the tumor.
Based on these results, it was concluded that the intermediate-
stage HCC (BCLC stage B) was downstaged to an early stage
HCC (BCLC stage A). A laparoscopic hepatectomy was
performed for the main nodule. The macroscopic and micro-
scopic histopathological examinations showed necrosis of HCC
with no tumor cells observed on the resection margins, and the
pathological diagnosis was necrotic nodule (Fig. 1d-f). There was
no clinical evidence of recurrence at 6 months after the resection.
The AFP levels remained within the normal limits.
2.2. Case 2
A 72-year-old woman had been followed-up for nonalcoholic
steatohepatitis. The cirrhosis was classified as Child-Pugh 5 and
mALBI grade 2A. A liver tumor was detected by periodic
abdominal ultrasonography. Abdominal dynamic CT demon-
strated an enhancement in the arterial phase and wash-out in the
late phase. Large hypervascular liver tumor in S3, measuring 5.8
cm, was detected along with many satellite nodules that were
disseminated in all the liver segments (Fig. 2a, b). Based on the
presence of typical arterial uptake with portal wash-out on
dynamic CT, a typical hypervascular HCC in BCLC stage B was
diagnosed. We initially performed cTAE, targeting the main
tumor. However, a CT examination after 1 month showed that
lipiodol was washed out from more than half of the tumor lesion
(Fig. 2c) and the tumor marker level increased rapidly. We then
decided to switch to MTA treatment to maintain sufficient
hepatic reserve function. LEN was orally administered at 8mg/
day. Hypertension (Grade 2) was observed at day 49 after the
initiation of LEN therapy. After about 2 months of LEN
treatment, the patient exhibited PR (according to RECIST and the
Table 1














Case1 68/M Alcohol 1 B 5 1 75 PR/PR Hepatectomy None
Case2 71/F NASH 1 B 5 2a 100 PR/PR Hepatectomy None
Case3 70/M NASH 1 B 5 2a 100 PR/PR MWA Lenvatinib (6 months)
ALBI = albumin-bilirubin, BCLC= Barcelona Clinic Liver Cancer, CP = Child–Pugh, mRECIST =modified Response Evaluation Criteria in Solid Tumors, MWA =microwave ablation, PR= partial response, RDI=
relative dose intensity.
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mRECIST criteria). After 6 months of treatment, the main tumor
size had decreased considerably, with extensive necrotic areas
observed (Fig. 2d). No satellite nodes were detected (Fig. 2e).
Although no obvious staining lesion was observed, there was
still a concern that viable cells might remain in the main lesion.
Once the BCLC stage B HCC was downstaged to BCLC stage A,
we decided to perform left hepatectomy at 6 months after the
initiation of LEN therapy. LEN was discontinued for 10 days
before the surgery to prevent surgical complication.
The pathological diagnosis was moderate type HCC (Fig. 3a-
d). Finally, the patient was determined to have pathological stage
I disease, and curative resection was achieved. There were no
serious complications. At 3 months after hepatectomy, the
patients general condition was good and no tumor recurrence
was observed.
2.3. Case 3
A 73-year-old man presented with a history of alcoholic cirrhosis.
The cirrhosis was classified as Child-Pugh 5 and mALBI grade 1. A
dynamic CT scan showed a typical hypervascular HCC in S5,
measuring 5.2cm, and many satellite nodules located in S5/6
(Fig. 4a). Therefore, BCLC stage B was diagnosed. The patient was
initially treated with cTAE, targeting the main tumor (Fig. 4b).
However, follow-up CT examination after 1 month revealed that
more than half of the lipiodolwaswashed out from the target tumor
(Fig. 4c), suggesting that the tumor would eventually become
refractory to cTAE treatment. Therefore, we switched the treatment
to LENmonotherapy (oral administration at 12mg/day). No severe
side effects were seen, except for grade 2 hypertension. After 2
months of LEN treatment, PR was observed (according to the
RECIST and mRECIST criteria). LEN therapy was continued, and
the patients general condition was good. After 6 months of
treatment, subsequentCT scans revealed that the target lesion size in
themain tumor decreased from5.2cm to 2cmand no satellite nodes
were detected (Fig. 4d). Therefore, it was concluded that HCC in
BCLC stage B was downstaged to BCLC stage A. LEN treatment
was interrupted for 1 week and the patient underwent cTAE on the
target lesion. Subsequently, microwave ablation was performed in
combination with artificial ascites (Fig. 4e, f). Next day, complete
cauterization of the target lesion was confirmed by CT evaluation.
LEN treatment was resumed after a 2-week interruption. No
recurrence was observed after 6 months of MTA treatment.
3. Discussion
Conversion therapy has been established as a therapeutic strategy
for the treatment of patients with gastrointestinal cancer with
Figure 1. Clinical images of ruptured hepatocellular carcinoma in a 69-year-old man (case 1). (a) Dynamic computerized tomography (CT) findings at initial
diagnosis. CT images showed a large hypervascular liver tumor in segment 6, measuring 7.3cm. (b) CT findings after conventional-transcatheter arterial
embolization treatment. (c) CT findings after 6months of LEN treatment showed that the tumor burden had decreased. (d) Image of the resected specimen obtained
after laparoscopic hepatectomy. (e, f) Histological findings from the main tumor (hematoxylin and eosin stain). There were no tumor cells on resection margins.
Pathological diagnosis revealed a necrotic nodule.
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unresectable metastases, controlled by chemotherapy and
additional surgical resection. However, the feasibility and
efficacy of conversion therapy in HCC have not been studied
well. Considering its high objective response rate and low impact
on liver function, LEN therapy could be expected to achieve
downstaging of tumors and lead to conversion therapy with
surgical procedure.
In this context, we defined the indication of conversion therapy
in patients who could achieve downstaging of HCC from BCLC
stage B to BCLC stage A after treatment with LEN. Data from
3 patients, who successfully achieved conversion therapy by
surgical resection or ablation, are presented in this report, and the
clinical characteristics and courses are summarized in Table 1.
Before the approval of LEN, SOR was prescribed as the first-
line treatment for HCC. To date, there have been few reported
cases of HCC patients who underwent conversion therapy after
SOR treatment, leading to long-term survival.[5–7] This may be
due to the fact that SOR monotherapy can rarely downstage
unresectable HCC to resectable stage, due to a low response rate
of 12.4%, according to the mRECIST.[2] In contrast, LEN has
demonstrated a significantly higher response rate than other
MTAs, which is reported to be extremely high at 40.6% by
independent imaging review (according to the mRECIST).[2] The
high tumor shrinkage rate of LEN might have resulted in the
downstaging of HCC patients. Additionally, the maintenance of
better liver function in all the patients before the initiation of LEN
treatment could have contributed to the downstaging in these
patients. These results reiterate the observation that better
hepatic reserve function is associated with the therapeutic effect
of LEN.[8–10] It has also been reported that the relative dose
intensity (RDI) plays an important role in the therapeutic effect of
LEN.[8,11,12] In all of our cases, hepatic reserve function was good
and the RDI, up to the first imaging evaluation, was high (Case 1:
75%, Case 2: 100%, Case 3: 100%) (Table 1). Although in
BCLC stage B, cTACE/TAE is a standard treatment for
unresectable HCC, Arizumi et al and Ogasawara et al reported
that the switch from cTACE to SOR significantly improved the
OS in patients with intermediate-stage HCCwho were refractory
to cTACE therapy. Therefore, they suggested that administration
of SOR is recommended in patients who are unresponsive to
cTACE, when appropriate.[13,14] Furthermore, Kudo et al have
reported that it is more effective to use LEN before cTACE in
BCLC stage B cases, suggesting the importance of early initiation
of LEN therapy.[15] Considering these reports, we initially
performed cTAE for the main lesion, but only once so as to avoid
the development of resistance to TAE, and soon switched to LEN
monotherapy, which resulted in high response efficiency in all the
cases (Table 1).
For HCC patients, mRECIST is often used for the standard
assessment of treatment efficacy; particularly in patients who
receive antiangiogenic drugs.[16] However, there is some concern
as to whether mRECIST is appropriate to evaluate the
resectability of HCC, since it does not necessarily reflect the
actual tumor shrinkage and only evaluates the elimination of
tumor staining. In our cases, we used both mRECIST and
RECIST criteria to confirm the high response rate, which led to
Figure 2. Clinical images of nonalcoholic steatohepatitis-based hepatocellular carcinoma in a 72-year-old woman with (case 2). (a, b) Dynamic computerized
tomography (CT) findings at initial diagnosis showed a large hypervascular liver tumor in S3, measuring 5.8cm and many satellite nodules, disseminated in all the
liver segments. (c) CT findings after 1month showed that lipiodol was washed out frommore than half of the tumor lesion. (d, e) CT findings after 6months. Themain
tumor size had decreased. Extensive necrotic areas were observed, while no satellite nodes were detected.
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Figure 3. Clinical images of nonalcoholic steatohepatitis-based hepatocellular carcinoma in a 72-year-old woman with (Case 2). (a, b) The resected specimen
obtained after laparoscopic hepatectomy. The sections within the blue colored lines are viable cancer cells, while the sections within the yellow colored lines are
necrotic cells. (c, d) Histological findings from the main tumor (hematoxylin and eosin stain).
Figure 4. Clinical images of alcoholic cirrhosis-based hepatocellular carcinoma in a 73-year-old man (Case 3). (a, b) Dynamic computerized tomography (CT)
findings at initial diagnosis showed a large hypervascular liver tumor in S5, measuring 5.2cm, and many satellite nodules in S5/6 the liver segments. (c) CT findings
after 1 month showed that lipiodol was washed out from more than half of the tumor lesion. (d) CT findings after 6 months showed that the main tumor size had
decreased. (e) CT findings after conventional-transcatheter arterial embolization treatment. (f) CT findings after treated with microwave ablation.
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the decision of conversion therapy. In the resected specimens
from cases 1 and 2, the tumors became necrotic even at the site
where the tumor stain disappeared in mRECIST evaluation. In
addition, histopathological examination showed almost no
residual tumor in the resected liver tissues (Figs. 1 and 3). These
results demonstrated the usefulness of mRECIST in deciding the
resectability of tumors. However, further data is required to
verify this result.
The efficacy and safety of SOR treatment in HCC patients with
spontaneous rupture have been reported previously.[17] Howev-
er, there were no reports on LEN treatment in this patient
population. Rupture of HCC can lead to peritoneal dissemina-
tion and recurrence. Therefore, we suggest that LEN should be
available for HCC patients with spontaneous rupture, as
presented in case 1.
LEN targets various receptors, including VEGF 1–3, FGF 1–
4, PDGF a, RET, and KIT.[18–20] Hence, LEN treatment is
discontinued peri-operatively if surgical or ablation procedures
are required, since the antiangiogenic effects of LEN can result
in complications, such as delayed healing and bleeding.
However, there is no established protocol for the appropriate
timing of LEN interruption. Since the half-life of LEN is
approximately 28 to 35h,[21] the duration of interruption of
pre-operation or pre-ablation needs to be at least 1 week,
considering the safety margin. The pre-operation or pre-
ablation was 7 days in cases 1 and 3, and 64 days in case 2. The
latter needed urgent pacemaker implantation for the treatment
for the AV block, unrelated to the administration of LEN. As a
result, no obvious complications were observed after the
operation in all the cases.
It is not clear whether continuation of LEN treatment after
resection of HCC would be effective, since the results of the
STORM study (SOR administered to HCC patients in
postoperative setting) were negative.[22] Therefore, we adminis-
tered adjuvant LEN treatment only to the patient who received
ablation treatment (case 2), since we could not completely rule
out the possibility of the presence of residual tumor. After 6
months of LEN monotherapy, treatment was discontinued once
no recurrence was confirmed. In all the cases, no recurrence was
seen during the observation period (median 8 months, range 6–
8). However, further prospective studies may be needed to
demonstrate whether adjuvant LEN is required after conversion
therapy.
Since this report is limited by its short observation period and
retrospective nature, our results do not necessarily demonstrate
that surgical resection or ablation improve overall survival per se.
Therefore, in the future, more studies need to be conducted to
investigate the therapeutic efficacy of conversion therapy
using LEN.
4. Conclusions
In conclusion, the results from this study demonstrated that LEN
enables downstaging of HCC, and thus represents a bridge to
successful surgery or ablation therapy. In particular, cases with
Child-Pugh 5 and m-ALBI 1, 2a were more likely to be able to
switch to conversion therapy. Overall, the results indicate that
treatment with LEN may improve the possibility for resection of
unresectable HCC, while maintaining better hepatic functional
reserve. Therefore, the initial incurability of patients with
unresectable HCC should be reconsidered when the patients
respond well to LEN because long-term survival may be expected
in these patients with conversion therapy. Nevertheless, the
results from this study need to be further validated in large scale
prospective studies.
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